Výsledky vyhledávání - "Rosemina Merchant"

Abstract 5532: An ‘anti-PD1-IL2 beta-only super-agonist’ displays potent anti-tumor efficacy

Autor: Minh D. To, Manjunatha Ankathatti Munegowda, Rosemina Merchant, Aanchal Sharma

Publikováno v: Cancer Research. 82:5532-5532

Introduction: Combination studies with engineered IL-2 variants and immune-checkpoint blockade have demonstrated synergy in both pre-clinical models and the clinic. Co-administration of those 2 agents can potentially face challenges related to overla

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c2b2ecaf1abe7c7b19b2ec1fa972951c
https://doi.org/10.1158/1538-7445.am2022-5532

Zobrazit plný text záznamu

Abstract P198: MDNA11 is a long-acting ‘beta-only’ IL-2 agonist that demonstrates a safe and durable anti-tumor immune response

Autor: Minh D. To, Fahar Merchant, Ma'an Muhsin, Carole Galligan, L. Bruce Pearce, Peter Lloyd, Rosemina Merchant

Publikováno v: Molecular Cancer Therapeutics. 20:P198-P198

Background: MDNA11 is an engineered ‘beta-only’ IL-2 superkine with (1) enhanced affinity for IL-2Rb (CD122) to preferentially activate anti-cancer effector immune cells and (2) extended half-life by fusion to human albumin, avoiding the need for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::356e9a5de15404e0dd0ae9605df2d646
https://doi.org/10.1158/1535-7163.targ-21-p198

Zobrazit plný text záznamu

ATIM-05. INTRATUMORAL DELIVERY OF MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, BY MRI-GUIDED CONVECTIVE DELIVERY FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA

Autor: Fahar Merchant, Krystof S. Bankiewicz, Martin Bexon, Achal S. Achrol, Nicholas Butowski, Andrew Brenner, Michael A. Vogelbaum, Dina Randazzo, Santosh Kesari, Rosemina Merchant, John Sampson, Miroslaw Zabek

Publikováno v: Neuro-Oncology. 20:vi1-vi2

While intratumoral delivery of immunotherapies allows for targeted distribution and minimal systemic toxicity, optimal spatial distribution of therapeutic agents remains a challenge. MR-guided convection-enhanced delivery of MDNA55, interleukin-4 cyt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a547f243a5800d0a5d99e45b14d50c9a
https://doi.org/10.1093/neuonc/noy148.002

Zobrazit plný text záznamu

MDNA109: Effect of an interleukin-2 superkine on CD8 T-cell properties in the tumor microenvironment

Autor: Fahar Merchant, Shafique Fidai, Rosemina Merchant, Moutih Rafei

Publikováno v: Journal of Clinical Oncology. 37:e14220-e14220

e14220 Background: Proleukin (a cysteine-modified variant of interleukin (IL)-2) is the only common-γc cytokine approved for the treatment of metastatic melanoma and renal cell carcinoma. Its therapeutic use is however hampered by its short half-lif

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3b0c5c1d4d6dd14927ffdc74867ac9d5
https://doi.org/10.1200/jco.2019.37.15_suppl.e14220

Zobrazit plný text záznamu

Prospective, Randomized, Double-Blind, Vehicle Controlled, Multicenter Phase IIb Clinical Trial of the Pore Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia

Autor: Rosemina Merchant, Samuel R. Denmeade, Richard C. Yocum, Mostafa M. Elhilali, Claus G. Roehrborn, Peter Pommerville

We conducted a safety and efficacy evaluation of intraprostatic injection of PRX302, a modified pore forming protein (proaerolysin) activated by prostate specific antigen, as a highly targeted, localized approach to treat lower urinary tract symptoms

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c0347869c9345f2103fc224e1daad8b
https://europepmc.org/articles/PMC3740739/

Zobrazit plný text záznamu

Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

Autor: Samuel R. Denmeade, Ralph J. Abi-Habib, Blair Egerdie, Rosemina Merchant, Peter Pommerville, Gary Steinhoff

Publikováno v: European urology. 59(5)

PRX302 is a prostate specific antigen (PSA)-activated pore-forming protein toxin under development as a targeted approach for improving lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) without affecting sexual function

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36414ebd829f94ce1a15cf90faaaeddc
https://pubmed.ncbi.nlm.nih.gov/22494739

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání